LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115955 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Junya Arima und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, RNA, Long Noncoding, Exosomes, Biomarkers, Tumor. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaken Pharmaceutical (Japan), Japan Society for the Promotion of Science KAKENHI, Kodama Memorial Fund for Medical Research.
Abstract (Originalsprache)
Bladder cancer (BC) is a common genitourinary malignancy that exhibits silent morbidity and high mortality rates because of a lack of diagnostic markers and limited effective treatments. Here, we evaluated the role of the lncRNA brain cytoplasmic RNA 1 (BCYRN1) in BC. We performed loss-of-function assays to examine the effects of BCYRN1 downregulation in T24 and BOY BC cells. We found that BCYRN1 downregulation significantly inhibited the proliferation, migration, invasion, and three-dimensional spheroid formation ability and induced apoptosis in BC cells. Additionally, gene set enrichment analysis (GSEA) using RNA sequences from tumor fractions showed that BCYRN1 downregulation decreased the expression of mRNAs associated with the cell cycle. These findings were supported by observations of G2/M arrest in flow cytometry assays. Finally, we examined the expression of serum exosomal BCYRN1 as a biomarker. Clinically, BCYRN1 expression in serum exosomes from patients with BC (n = 31) was significantly higher than that in healthy donors (n = 19; mean difference: 4.1-fold higher, p < 0.01). Moreover, in patients who had undergone complete resection of BC, serum exosomal BCYRN1 levels were significantly decreased (n = 8). Thus, serum exosomal BCYRN1 may be a promising diagnostic marker and therapeutic target in patients with BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.
ORCID-Profile: Junya Arima, Hirofumi Yoshino, Shuichi Tatarano
Förderung
- Kaken Pharmaceutical (Japan)
- Japan Society for the Promotion of Science KAKENHI
- Kodama Memorial Fund for Medical Research
Zitieren
APA
Arima, J., Yoshino, H., Fukumoto, W., Kawahara, I., Saito, S., Li, G., Fukuda, I., Iizasa, S., Mitsuke, A., Sakaguchi, T., Inoguchi, S., Matsushita, R., Nakagawa, M., Tatarano, S., Yamada, Y., & Enokida, H. (2024). LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115955
Vancouver
Arima J, Yoshino H, Fukumoto W, Kawahara I, Saito S, Li G, et al. LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115955
BibTeX
@article{Arima2024,
author = {Arima, Junya and Yoshino, Hirofumi and Fukumoto, Wataru and Kawahara, Ichiro and Saito, Saeki and Li, Gang and Fukuda, Ikumi and Iizasa, Sayaka and Mitsuke, Akihiko and Sakaguchi, Takashi and Inoguchi, Satoru and Matsushita, Ryosuke and Nakagawa, Masayuki and Tatarano, Shuichi and Yamada, Yasutoshi and Enokida, Hideki},
title = {LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115955}
}
EUVIMED